The ubiquitin-proteasome system and cardiovascular disease

Saul R. Powell, Joerg Herrmann, Amir Lerman, Cam Patterson, Xuejun Wang

Research output: Chapter in Book/Report/Conference proceedingChapter

49 Citations (Scopus)

Abstract

Over the past decade, the role of the ubiquitin-proteasome system (UPS) has been the subject of numerous studies to elucidate its role in cardiovascular physiology and pathophysiology. There have been many advances in this field including the use of proteomics to achieve a better understanding of how the cardiac proteasome is regulated. Moreover, improved methods for the assessment of UPS function and the development of genetic models to study the role of the UPS have led to the realization that often the function of this system deviates from the norm in many cardiovascular pathologies. Hence, dysfunction has been described in atherosclerosis, familial cardiac proteinopathies, idiopathic dilated cardiomyopathies, and myocardial ischemia. This has led to numerous studies of the ubiquitin protein (E3) ligases and their roles in cardiac physiology and pathophysiology. This has also led to the controversial proposition of treating atherosclerosis, cardiac hypertrophy, and myocardial ischemia with proteasome inhibitors. Furthering our knowledge of this system may help in the development of new UPS-based therapeutic modalities for mitigation of cardiovascular disease.

Original languageEnglish (US)
Title of host publicationProgress in Molecular Biology and Translational Science
PublisherElsevier B.V.
Pages295-346
Number of pages52
DOIs
StatePublished - 2012

Publication series

NameProgress in Molecular Biology and Translational Science
Volume109
ISSN (Print)1877-1173

Fingerprint

Proteasome Endopeptidase Complex
Ubiquitin
Cardiovascular Diseases
Myocardial Ischemia
Atherosclerosis
Cardiovascular Physiological Phenomena
Proteasome Inhibitors
Ubiquitin-Protein Ligases
Genetic Models
Dilated Cardiomyopathy
Cardiomegaly
Proteomics
Pathology

Keywords

  • Atherosclerosis
  • Cardiomyopathy
  • Heart
  • Heart failure
  • Myocardial ischemia
  • Preconditioning
  • Protein quality control
  • Ubiquitin protein ligases
  • Ubiquitin-proteasome system
  • Vascular

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology

Cite this

Powell, S. R., Herrmann, J., Lerman, A., Patterson, C., & Wang, X. (2012). The ubiquitin-proteasome system and cardiovascular disease. In Progress in Molecular Biology and Translational Science (pp. 295-346). (Progress in Molecular Biology and Translational Science; Vol. 109). Elsevier B.V.. https://doi.org/10.1016/B978-0-12-397863-9.00009-2

The ubiquitin-proteasome system and cardiovascular disease. / Powell, Saul R.; Herrmann, Joerg; Lerman, Amir; Patterson, Cam; Wang, Xuejun.

Progress in Molecular Biology and Translational Science. Elsevier B.V., 2012. p. 295-346 (Progress in Molecular Biology and Translational Science; Vol. 109).

Research output: Chapter in Book/Report/Conference proceedingChapter

Powell, SR, Herrmann, J, Lerman, A, Patterson, C & Wang, X 2012, The ubiquitin-proteasome system and cardiovascular disease. in Progress in Molecular Biology and Translational Science. Progress in Molecular Biology and Translational Science, vol. 109, Elsevier B.V., pp. 295-346. https://doi.org/10.1016/B978-0-12-397863-9.00009-2
Powell SR, Herrmann J, Lerman A, Patterson C, Wang X. The ubiquitin-proteasome system and cardiovascular disease. In Progress in Molecular Biology and Translational Science. Elsevier B.V. 2012. p. 295-346. (Progress in Molecular Biology and Translational Science). https://doi.org/10.1016/B978-0-12-397863-9.00009-2
Powell, Saul R. ; Herrmann, Joerg ; Lerman, Amir ; Patterson, Cam ; Wang, Xuejun. / The ubiquitin-proteasome system and cardiovascular disease. Progress in Molecular Biology and Translational Science. Elsevier B.V., 2012. pp. 295-346 (Progress in Molecular Biology and Translational Science).
@inbook{5fe280cbe4894b6ab197be47a4c6c34a,
title = "The ubiquitin-proteasome system and cardiovascular disease",
abstract = "Over the past decade, the role of the ubiquitin-proteasome system (UPS) has been the subject of numerous studies to elucidate its role in cardiovascular physiology and pathophysiology. There have been many advances in this field including the use of proteomics to achieve a better understanding of how the cardiac proteasome is regulated. Moreover, improved methods for the assessment of UPS function and the development of genetic models to study the role of the UPS have led to the realization that often the function of this system deviates from the norm in many cardiovascular pathologies. Hence, dysfunction has been described in atherosclerosis, familial cardiac proteinopathies, idiopathic dilated cardiomyopathies, and myocardial ischemia. This has led to numerous studies of the ubiquitin protein (E3) ligases and their roles in cardiac physiology and pathophysiology. This has also led to the controversial proposition of treating atherosclerosis, cardiac hypertrophy, and myocardial ischemia with proteasome inhibitors. Furthering our knowledge of this system may help in the development of new UPS-based therapeutic modalities for mitigation of cardiovascular disease.",
keywords = "Atherosclerosis, Cardiomyopathy, Heart, Heart failure, Myocardial ischemia, Preconditioning, Protein quality control, Ubiquitin protein ligases, Ubiquitin-proteasome system, Vascular",
author = "Powell, {Saul R.} and Joerg Herrmann and Amir Lerman and Cam Patterson and Xuejun Wang",
year = "2012",
doi = "10.1016/B978-0-12-397863-9.00009-2",
language = "English (US)",
series = "Progress in Molecular Biology and Translational Science",
publisher = "Elsevier B.V.",
pages = "295--346",
booktitle = "Progress in Molecular Biology and Translational Science",

}

TY - CHAP

T1 - The ubiquitin-proteasome system and cardiovascular disease

AU - Powell, Saul R.

AU - Herrmann, Joerg

AU - Lerman, Amir

AU - Patterson, Cam

AU - Wang, Xuejun

PY - 2012

Y1 - 2012

N2 - Over the past decade, the role of the ubiquitin-proteasome system (UPS) has been the subject of numerous studies to elucidate its role in cardiovascular physiology and pathophysiology. There have been many advances in this field including the use of proteomics to achieve a better understanding of how the cardiac proteasome is regulated. Moreover, improved methods for the assessment of UPS function and the development of genetic models to study the role of the UPS have led to the realization that often the function of this system deviates from the norm in many cardiovascular pathologies. Hence, dysfunction has been described in atherosclerosis, familial cardiac proteinopathies, idiopathic dilated cardiomyopathies, and myocardial ischemia. This has led to numerous studies of the ubiquitin protein (E3) ligases and their roles in cardiac physiology and pathophysiology. This has also led to the controversial proposition of treating atherosclerosis, cardiac hypertrophy, and myocardial ischemia with proteasome inhibitors. Furthering our knowledge of this system may help in the development of new UPS-based therapeutic modalities for mitigation of cardiovascular disease.

AB - Over the past decade, the role of the ubiquitin-proteasome system (UPS) has been the subject of numerous studies to elucidate its role in cardiovascular physiology and pathophysiology. There have been many advances in this field including the use of proteomics to achieve a better understanding of how the cardiac proteasome is regulated. Moreover, improved methods for the assessment of UPS function and the development of genetic models to study the role of the UPS have led to the realization that often the function of this system deviates from the norm in many cardiovascular pathologies. Hence, dysfunction has been described in atherosclerosis, familial cardiac proteinopathies, idiopathic dilated cardiomyopathies, and myocardial ischemia. This has led to numerous studies of the ubiquitin protein (E3) ligases and their roles in cardiac physiology and pathophysiology. This has also led to the controversial proposition of treating atherosclerosis, cardiac hypertrophy, and myocardial ischemia with proteasome inhibitors. Furthering our knowledge of this system may help in the development of new UPS-based therapeutic modalities for mitigation of cardiovascular disease.

KW - Atherosclerosis

KW - Cardiomyopathy

KW - Heart

KW - Heart failure

KW - Myocardial ischemia

KW - Preconditioning

KW - Protein quality control

KW - Ubiquitin protein ligases

KW - Ubiquitin-proteasome system

KW - Vascular

UR - http://www.scopus.com/inward/record.url?scp=84862741327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862741327&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-397863-9.00009-2

DO - 10.1016/B978-0-12-397863-9.00009-2

M3 - Chapter

C2 - 22727426

AN - SCOPUS:84862741327

T3 - Progress in Molecular Biology and Translational Science

SP - 295

EP - 346

BT - Progress in Molecular Biology and Translational Science

PB - Elsevier B.V.

ER -